Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study

Lung Cancer

Volumn 75, Issue 3, 2012, Pages 353-359

  Kuribayashi, Kozo ^a   Voss, Simon ^b   Nishiuma, Shinichi ^b   Arakawa, Kimiko ^b   Nogi, Yoshitaka ^a   Mikami, Koji ^a   Kudoh, Shoji ^c  

^a ASAHI UNIVERSITY   (Japan)

^b ELI LILLY AND COMPANY   (United States)

^c Japan Anti Tuberculosis Association   (Japan)

Author keywords

Cisplatin; Interstitial; Japan; Lung diseases; Mesothelioma; Pemetrexed; Postmarketing surveillance

Indexed keywords

ASBESTOS; CARBOPLATIN; CISPLATIN; FOLIC ACID; GEMCITABINE; GOSERELIN; NAVELBINE; PEMETREXED;

ADULT; AGED; ANEMIA; ANOREXIA; APPETITE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENVIRONMENTAL EXPOSURE; FEMALE; GLOMERULUS FILTRATION RATE; HICCUP; HISTOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SIDE EFFECT; THERAPY DELAY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; UREA BLOOD LEVEL; VITAMIN SUPPLEMENTATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; GLUTAMATES; GUANINE; HUMANS; JAPAN; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84856577604     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.08.002     Document Type: Article

References (20)

1. Nakano T. Current therapies for malignant pleural mesothelioma. Environ Health Prev Med 2008, 13:75-83.
2. Robinson B.W., Lake R.A. Advances in malignant mesothelioma. N Engl J Med 2005, 353:1591-1603.
3. Azuma K., Uchiyama I., Chiba Y., Okumura J. Mesothelioma risk and environmental exposure to asbestos: past and future trends in Japan. Int J Occup Environ Health 2009, 15:166-172.
4. Adjei A.A. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004, 10:4276-4280.
5. Scagliotti G.V., Ceppi P., Capelletto E., Novello S. Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer 2009, 10(Suppl 1):S35-S40.
6. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Pierre R., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
7. Van Meerbeeck J.P., Gaafar R., Manegold C., van Klaveren R.J., Van Marck E.A., Vincent M., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23:6881-6889.
8. Martino D., Pass H.I. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer 2004, 5:290-298.
9. Solomon B., Bunn P.A. Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent. Fut Oncol 2005, 1:733-746.
10. Nakagawa K., Yamazaki K., Kunitoh H., Hida T., Gemba K., Shinkai T., et al. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients. Jpn J Clin Oncol 2008, 38:339-346.
11. Camus P., Kudoh S., Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004, 91(Suppl 2):S18-S23.
12. Danson S., Blackhall F., Hulse P., Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 2005, 28:103-113.
13. Maintenance of the ICH guideline on clinical safety data management: data elements for transmission of individual case safety reports E2B(R2).
14. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
15. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15:257-260.
16. Nojiri S., Gemba K., Aoe K., Kato K., Yamaguchi T., Sato T., et al. Incidence of interstitial lung disease in patients with mesothelioma in the west part of Japan. Pharmacoepidemiol Drug Saf 2011, 20:643-652.
17. Drug Approval Package; Alimta (Pemetrexed for injection). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-462_Alimta.cfm.
18. Santoro A., O'Brien M.E., Stahel R.A., Nackaerts K., Baas P., Karhaus M., et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the international expanded access program. J Thoracic Oncol 2008, 3:756-763.
19. Sugarbaker D.J., Strauss G.M., Lynch T.J., Richards W., Mentzer S.J., Lee T.H., et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993, 11:1172-1178.
20. Nojiri S., Gemba K., Aoe K., Kato K., Yamaguchi T., Sato T., et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the West part of Japan. Jpn J Clin Oncol 2010, 41:32-39.